Joinder to Joint Filing AgreementJoinder to Joint Filing Agreement • January 21st, 2015 • F2 Bioscience III, L.P. • Pharmaceutical preparations
Pursuant to Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned agrees that this Statement on Schedule 13D, as amended, and any subsequent amendments thereto, to which this exhibit is attached, is filed on its behalf in the capacity set forth below and hereby joins the Joint Filing Agreement by and among F2 Bioscience III, LP, F2 Bioscience GP, Ltd., Morana Jovan-Embiricos, Katherine Priestley and F2 Capital Limited, dated May 2, 2013.
